Connecticut is currently home to 1218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT04084730
Recruiting
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in women with newly diagnosed breast cancer or DCIS who have had a lumpectomy procedure.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
04/23/2025
Locations: Norwalk Hospital, Norwalk, Connecticut
Conditions: Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1, DCIS Grade 2, Breast Cancer
Register for Updates
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075
Recruiting
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2025
Locations: CT Clinical Research, Cromwell, Connecticut
Conditions: Acute Migraine
Register for Updates
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT06735755
Recruiting
This is a Phase 1/2, multicenter, open-label, single-ascending-dose study to evaluate the safety, tolerability, and efficacy of BEAM-301 in adult patients with GSDIa homozygous or compound heterozygous for the G6PC1 c.247C\>T (p.R83C) variant and to determine the optimal biological dose.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Clinical Study Site, Farmington, Connecticut
Conditions: Glycogen Storage Disease Type Ia
Register for Updates
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
04/22/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Amblyopia
Register for Updates
Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)
NCT06214065
Recruiting
The goal of this observational study is to test the modulation effect of different transcranial magnetic stimulation (TMS) on the neural network supporting our ability to create mental representations of others (also known as mentalizing) in young adults with autism. The main question it aims to answers is can stimulation of the right temporoparietal junction can change brain activity related to mentalizing during social interaction in the stimulation area and other brain areas connected to it.... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
04/22/2025
Locations: Olin Neuropsychiatry Research Center (ONRC), Hartford, Connecticut
Conditions: Autism Spectrum Disorder
Register for Updates
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612
Recruiting
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Register for Updates
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
NCT06050252
Recruiting
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Resectable Intrahepatic Cholangiocarcinoma
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/22/2025
Locations: Research Site, Hartford, Connecticut
Conditions: Acute Coronary Syndrome
Register for Updates
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
04/22/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Register for Updates
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT05554406
Recruiting
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to t... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
04/22/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Register for Updates
Stepped Care for Patients to Optimize Whole Recovery
NCT05155163
Recruiting
This is a prospective, randomized clinical trial of 204 patients with opioid use disorder (OUD) and chronic pain (CP) to test the effectiveness of treatment as usual compared with Stepped Care for Patients to Optimize Whole Recovery (SC-POWR) to reduce pain interference (Aim 1) and decrease illicit opioid use, alcohol use, anxiety, depression, and stress, and improve sleep (Aim 2). Eligible participants will begin medications for opioid use disorder (MOUD) and will be randomized to receive SC-PO... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: APT Foundation, New Haven, Connecticut
Conditions: Opioid Use Disorder, Chronic Pain
Register for Updates
Black Church Treatment Study
NCT04580810
Recruiting
This study will conduct a randomized clinical trial comparing levels of treatment initiation, engagement, and alcohol outcomes for a novel treatment strategy (CBT4CBT delivered in the Black church) compared with traditional outpatient specialty addiction treatment for a large sample of Black adults with AUD. The purpose of this randomized clinical trial is to determine which setting (church or specialty clinic) (1) has better treatment initiation and retention rates and (2) better AUD outcomes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Beulah Heights First Pentecostal Church, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Register for Updates